1. Deeks, SG, Tracy, R, Douek, DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39: 633–645.
Google Scholar | Crossref | Medline | ISI2. Nou, E, Lo, J, Hadigan, C, et al. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol 2016; 4: 598–610.
Google Scholar | Crossref | Medline3. Triant, VA, Lee, H, Hadigan, C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506–2512.
Google Scholar | Crossref | Medline | ISI4. Currier, JS, Taylor, A, Boyd, F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506–512.
Google Scholar | Crossref | Medline | ISI5. Freiberg, MS, Chang, CC, Kuller, LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614–622.
Google Scholar | Crossref | Medline | ISI6. Feinstein, MJ, Hsue, PY, Benjamin, LA, et al.; on behalf of the American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention and Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation 2019; 140: e98–e124.
Google Scholar | Crossref | Medline7. Grundy, SM, Stone, NJ, Bailey, AL, et al. 2018 ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: 3168–3209.
Google Scholar | Crossref | Medline8. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486–2497.
Google Scholar | Crossref | Medline | ISI9. Dubé, MP, Stein, JH, Aberg, JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613–627.
Google Scholar | Crossref | Medline | ISI10. Levy, ME , et al. Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-Infected outpatients. AIDS Patient Care STDs 2018; 32: 58–431.
Google Scholar | Crossref | Medline11. Mosepele, M, Regan, S, Massaro, J, et al. Impact of the American College of Cardiology/American Heart Association cholesterol guidelines on statin eligibility among human immunodeficiency virus-Infected individuals. Open Forum Infect Dis 2018; 5: 1–7.
Google Scholar | Crossref12. Schafer, J, Patel, R, Hastain, N, et al. Patients living with HIV infection are less likely to receive the correct intensity of statin therapy for cardiovascular disease risk reduction. In: IDWeek 2019, 2–6 October 2019, Washington, DC.
Google Scholar13. Riestenberg, RA, Furman, A, Cowen, A, et al. Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons. Am Heart J 2019; 209: 79–87.
Google Scholar | Crossref | Medline14. Stone, NJ, Robinson, JG, Lichtenstein, AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College Of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934.
Google Scholar | Crossref | Medline | ISI15. National Center for Chronic Disease Prevention and Health Promotion . Calculating proportion of days covered (PDC) for antihypertensive and antidiabetic medications: an evaluation guide for grantees, www.cdc.gov/dhdsp/docs/med-adherence-evaluation-tool.pdf (accessed 30 June 2020).
Google Scholar16. Rosenson, RS, Colantonio, LD, Burkholder, GA, et al. Trends in utilization of statin therapy and contraindicated statin use in HIV-infected adults treated with antiretroviral therapy from 2007 through 2015. J Am Heart Assoc 2018; 7: e010345.
Google Scholar | Crossref | Medline17. Chastain, DB, Stover, KR, Riche, DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol 2017; 8: 6–14.
Google Scholar | Medline18. Holtzman, CW, Brady, KA, Yehia, BR. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs 2015; 75: 445–454.
Google Scholar | Crossref | Medline19. Iacob, SA, Iacob, DG, Jugulete, G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol 2017; 8: 831.
Google Scholar | Crossref | Medline20. Beer, L, Tie, Y, Weiser, J, et al. Nonadherence to any prescribed medication due to costs among adults with HIV infection – United States, 2016-2017. MMWR Morb Mortal Wkly Rep 2019; 68: 1129–1133.
Google Scholar | Crossref | Medline21. Langness, J, Cook, PF, Gill, J, et al. Comparison of adherence rates for antiretroviral, blood pressure, or mental health medications for HIV-positive patients at an academic medical center outpatient pharmacy. J Manag Care Spec Pharm 2014; 20: 809–814.
Google Scholar | Medline22. Moore, RD, Bartlett, JG, Gallant, JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS One 2011; 6: e21843.
Google Scholar | Crossref | Medline23. Funderburg, NT, Jiang, Y, Debanne, SM, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr 2015; 68: 396–404.
Google Scholar | Crossref | Medline24. Drechsler, H, Ayers, C, Cutrell, J, et al. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. BMC Infect Dis 2021; 21: 150.
Google Scholar | Crossref | Medline25. Grimspoon, Sk , et al. Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE). Am Heart J 2019; 212: 23–35.
Google Scholar | Crossref | Medline26. Renner, HM, Hollar, A, Stolpe, SF, et al. Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes: a randomized controlled trial. J Am Pharm Assoc (2003) 2017; 57: S236–S242.e1.
Google Scholar | Crossref | Medline27. Haby, HE, Alm, RA, Corona, AR, Hall, AC. Population health model for pharmacist assessment and independent prescribing of statins in an ambulatory care setting. J Am Pharm Assoc (2003) 2020; 60: 130–137.
Google Scholar | Crossref | Medline28. Anderson, SJ, Marrs, JC, Chachas, CR, et al. Evaluation of a pharmacist-led intervention to improve statin use in persons with diabetes. J Manag Care Spec Pharm 2020; 26: 910–917.
Google Scholar | Medline29. Troksa, KT, Billups, SJ, Claus, L, et al. Effectiveness of a pharmacist‐led population health approach to implementing statin therapy in primary prevention patients with type 2 diabetes mellitus. J Am Coll Clin Pharm 2020; 3: 723–728.
Google Scholar | Crossref